Jorik H Amesz
Overview
Explore the profile of Jorik H Amesz including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
16
Citations
24
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Bierhuizen M, Amesz J, Langmuur S, Lam B, Knops P, Veen K, et al.
Bioengineering (Basel)
. 2025 Feb;
12(2).
PMID: 40001693
Proof-of-concept to determine the direct biomechanical effects of cardiac contractility modulation (CCM) on living myocardial slices (LMS) from patients with end-stage heart failure (HF). Left ventricular LMS from patients with...
2.
Amesz J, Lupgens N, Duncker D, Sluijter-Rozendaal L, Dumay D, Manintveld O, et al.
ASAIO J
. 2025 Feb;
PMID: 39977384
Myocardial edema significantly develops during current subnormothermic ex situ heart perfusion (ESHP) procedures, resulting in myocardial function decline during prolonged perfusion. A relatively high coronary blood flow (CBF) during ESHP...
3.
Amesz J, Langmuur S, Bierhuizen M, de Groot N, Manintveld O, Taverne Y
J Mol Cell Cardiol Plus
. 2025 Jan;
5():100040.
PMID: 39802172
Heart failure (HF) is a rapidly growing pandemic while medical treatment options remain limited. Omecamtiv mecarbil (OM) is a novel HF drug that directly targets the myosin heads of the...
4.
van Doorn E, Amesz J, Manintveld O, de Groot N, Essers J, Shin S, et al.
Bioengineering (Basel)
. 2025 Jan;
11(12.
PMID: 39768038
Heart failure is characterized by intricate myocardial remodeling that impairs the heart's pumping and/or relaxation capacity, ultimately reducing cardiac output. It represents a major public health burden, given its high...
5.
Amesz J, Huijser E, Bevers R, Albersen A
Clin Chem
. 2024 Dec;
70(12):1497-1498.
PMID: 39667032
No abstract available.
6.
Amesz J, Bierhuizen M, Langmuur S, Dumay D, Manintveld O, Taverne Y, et al.
Ann Cardiothorac Surg
. 2024 Dec;
13(6):495-501.
PMID: 39649637
Background: Normothermic ex situ heart perfusion (ESHP) has increased the donor pool with hearts donated after circulatory death (DCD), but functional assessment during ESHP using lactate trends is suboptimal. This...
7.
Amesz J, Bierhuizen M, Langmuur S, Knops P, van Steenis Y, Dumay D, et al.
Transpl Int
. 2024 Dec;
37:13279.
PMID: 39635569
Normothermic heart perfusion (ESHP) enables assessment of hearts donated after circulatory death (DCD) prior to transplantation. However, sensitive parameters of cardiac function of DCD hearts on ESHP are needed. This...
8.
Amesz J, Taverne Y, Manintveld O
Eur Heart J
. 2024 Feb;
45(13):1177.
PMID: 38365963
No abstract available.
9.
Ramdat Misier N, Amesz J, Taverne Y, Nguyen H, van Schie M, Knops P, et al.
Heart Rhythm
. 2024 Jan;
21(6):819-827.
PMID: 38246568
Background: Atrial fibrillation (AF) in patients with hypertrophic obstructive cardiomyopathy (HOCM) may be caused by a primary atrial myopathy. Whether HOCM-related atrial myopathy affects mainly electrophysiological properties of the left...
10.
van Doorn E, Amesz J, Sadeghi A, de Groot N, Manintveld O, Taverne Y
Cardiovasc Eng Technol
. 2024 Jan;
15(2):232-249.
PMID: 38228811
For recent decades, cardiac diseases have been the leading cause of death and morbidity worldwide. Despite significant achievements in their management, profound understanding of disease progression is limited. The lack...